Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527394 | 0.91 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL21945473 | 0.84 | ALDH1A1 (0.45) | ALDH1A1LMNASMN1; SMN2NPSR1EPHX2 | |
| SCHEMBL14072550 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL19895701 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNASMN1; SMN2BPTFTSHR | |
| SCHEMBL19766894 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNATSHR | |
| SCHEMBL1566124 | 0.82 | POLB (0.58) | ALDH1A1LMNATSHR | |
| SCHEMBL14644921 | 0.81 | LMNA (0.60) | ALDH1A1LMNABPTFTSHRMAPT | |
| SCHEMBL8073717 | 0.81 | KMT2A (0.56) | ALDH1A1 | |
| SCHEMBL12834145 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNATSHR | |
| SCHEMBL1072911 | 0.80 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2NPSR1EPHX2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2019-08-22 | — | — | US | disclosed |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | ABBVIE INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180105530-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-19 | — | — | US | disclosed |
| EP-3286192-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co KG (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9828381-B2 | Substituted pyrazolopyrimidines and method of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-11-28 | — | — | US | disclosed |
| WO-2016169995-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-20 | — | — | US | disclosed |
| US-8178679-B2 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors | ALMIRALL, S.A. (ES) | 2012-05-15 | — | — | US | disclosed |
| US-20110008728-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110008728-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ALMIRALL, S.A. (ES) | 2010-12-23 | — | — | US | disclosed |
| EP-2212276-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068177-A1 | DERIVATIVES OF 4-(2-AMINO-1 -HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-06-04 | — | — | WO | disclosed |
| EP-0661271-B1 | AZEPINE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS SIGMA-RECEPTOR LIGANDS | ASAHI CHEMICAL IND (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5658923-A | USED IN TREATING DISEASES RELATED TO SIGMA-RECEPTOR, SUCH AS SCHIZOPHRENIA | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5650406-A | ANTISCHIZOPHRENIC AGENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0757040-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0661271-A1 | AZEPINE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304527-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | GABBR1, GABBR2, GABRB1 | ALDH1A1 258/4885LMNA 3878/4885SMN1; SMN2 772/4885 |
| US-10155770-B2 | Substituted pyrazolopyrimidines and method of use | GABBR1, GABBR2, GABRB1 | ALDH1A1 258/4885LMNA 3878/4885SMN1; SMN2 772/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | ALDH1A1 1679/4885LMNA 2092/4885SMN1; SMN2 2314/4885 |
| US-20100324000-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRA2C | ALDH1A1 497/4885LMNA 2577/4885SMN1; SMN2 3757/4885 |
| US-20190255041-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | ALDH1A1 2910/4885LMNA 1945/4885SMN1; SMN2 3483/4885 |
| US-20180105530-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE | GABBR1, GABBR2, GABRB1 | ALDH1A1 258/4885LMNA 3878/4885SMN1; SMN2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.